June 18-22, 2019 Lugano
![]() |
![]() |
![]() |
![]() |
136-P | One-year real-life targeted next generation sequencing for lymphoma diagnosis: study of patients from the French Lymphoma Network in Rhne-Alpes | Cme Bommier | ![]() |
![]() |
|||
137-P | MUTATIONAL LANDSCAPE OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT DIAGNOSIS AND AT PROGRESSION ASSESSED BY CIRCULATING TUMOR DNA ANALYSIS | Alfredo Rivas-Delgado | ![]() |
![]() |
|||
138-P | Targeted genotyping of circulating tumor DNA for classical Hodgkin Lymphoma monitoring: a prospective study | Vincent Camus | ![]() |
![]() |
|||
139-P | Analysis of Circulating Tumor DNA (ctDNA) in Cerebrospinal Fluid Detects the Presence of Central Nervous System (CNS) Involvement in B-Cell Lymphomas | Sabela Bobillo | ![]() |
![]() |
|||
140-P | Molecular analyses and an innovative diagnostic algorithm in MYC-negative Burkitt-like lymphoma with 11q aberration: a single institution experience | Grzegorz Rymkiewicz | ![]() |
![]() |
|||
141-P | High risk of adverse events after autologous stem-cell transplantation in lymphoma patients with DNA repair pathway mutations: A nation-wide cohort study | Simon Husby | ![]() |
![]() |
|||
144-P | Personalized prediction in DLBCL enabled by functional mouse genomics | Clemens A. Schmitt | ![]() |
![]() |
|||
146-P | Population-Based Outcomes in Large B-cell lymphoma by WHO Subtype: Findings from the UKs Haematological Malignancy Research Network | Russell Patmore | ![]() |
![]() |
|||
147-P | Refinement of MUM1 expression threshold for Double Positive CD10 MUM1 Diffuse Large B Cell Lymphoma allows a better Cell of Origin Classification for GCB subtype | Celine Bossard | ![]() |
![]() |
|||
148-P | Reduced BCL2 expression suggests alternative survival mechanisms in HIV() Diffuse Large B Cell Lymphoma (DLBCL) of Germinal Center Origin | Alanna Maguire | ![]() |
![]() |
|||
149-P | Single cell level analysis of MYC/ BCL2/ BCL6 co-expression in Diffuse large B-cell lymphoma through multiplexed quantitative immunofluorescence | Michelle Poon | ![]() |
![]() |
|||
150-P | Clinical significance of T-cell exhaustion in patients with diffuse large B-cell lymphoma | Sirpa Leppa | ![]() |
![]() |
|||
151-P | The influence of tumor immune microenvironment and tumor immunity on the pathogenesis, treatment and prognosis of post-transplant lymphoproliferative disorders (PTLD) | Saito Hideaki | ![]() |
![]() |
|||
152-P | JAK-STAT pathway and epigenetic regulators are critical players in BI-ALCL pathogenesis ? | Camille Laurent | ![]() |
![]() |
|||
153-P | Chromosome 20 loss is characteristic for Breast-implant Associated Anaplastic Large Cell Lymphoma | Bauke Ylstra | ![]() |
![]() |
|||
154-P | Whole Genome Sequencing Reveals Potential Therapeutic Strategy for MEITL | Dachuan Huang | ![]() |
![]() |
|||
155-P | Whole-genome sequencing reveals immunotherapeutic options for Natural-killer/T cell lymphoma patients. | Jing Quan Lim | ![]() |
![]() |
|||
156-P | KIR3DL2 Mutation may Define a High Rate of Response of AITL to Tipifarnib | antonio gualberto | ![]() |
![]() |
|||
158-P | A PTCL gene signature capturing stromal and neoplastic data stratifies PTCL/NOS and AITL into different groups with variable survival probability | Marta Rodriguez | ![]() |
![]() |
|||
159-P | Multicentric MFI30 study: standardization of CD30 expression by flow cytometry in Non-Hodgkin lymphoma. | Lucile BASEGGIO | ![]() |
![]() |
|||
160-P | Survival continues to increase in chronic lymphocytic leukemia: a population-based analysis among 20,324 patients diagnosed in the Netherlands between 1989 and 2015 | Lina van der Straten | ![]() |
![]() |
|||
161-P | Proteomics markers prognostic for outcome of chronic lymphocytic leukemia patients under treatment: results from the HOVON-109 study | Lina van der Straten | ![]() |
![]() |
|||
164-P | Hypertension (HTN) in Patients (Pts) treated with Ibrutinib (Ibr) for Chronic Lymphocytic Leukemia (CLL) | MARYAM SARRAF YAZDY | ![]() |
![]() |
|||
165-P | An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received 2 or more prior therapies | Ian Flinn | ![]() |
![]() |
|||
166-P | Effect of dose modifications on response to duvelisib in patients with relapsed/refractory CLL/SLL in the DUO trial | Paolo Ghia | ![]() |
![]() |
|||
167-P | Patterns of duvelisib-induced lymphocytosis in patients with R/R CLL or SLL including those with high-risk factors treated in the DUO trial | Jacqueline Barrientos | ![]() |
![]() |
|||
168-P | Brief co-administration of idelalisib may improve the long-term efficacy of frontline chemoimmunotherapy in chronic lymphocytic leukaemia: 3-year follow-up from the RIAltO trial | Andrew Pettitt | ![]() |
![]() |
|||
170-P | Long term follow up of FoRT: A Phase 3 Multi-Center Prospective Randomized Trial of Radiation Therapy for Follicular and Marginal Zone Lymphoma | Amy Kirkwood | ![]() |
![]() |
|||
171-P | Systemic therapy after Radiation Therapy in stage I-II follicular lymphoma: Final results of an International Randomized Trial TROG 99.03 | Michael MacManus | ![]() |
![]() |
|||
172-P | Results of a Multicenter Phase2 Trial of Involved Field Radiotherapy Alone for Localized Non-Gastric Marginal Zone Lymphoma: TROG 05.02 | Michael MacManus | ![]() |
![]() |
|||
173-P | Outcomes of 180 Patients with Indolent Lymphomas Treated with Very Low Dose (4 Gy) Radiation Therapy Alone | Karen Chau | ![]() |
![]() |
|||
175-P | FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY | Simone Ferrero | ![]() |
![]() |
|||
176-P | Rituximab alone (R) versus rituximab plus bendamustine (BR) for splenic (SMZL) and nodal marginal zone lymphoma (NMZL). | Adam Olszewski | ![]() |
![]() |
|||
180-P | Outcomes after early transformation (tPOD24) vs. early follicular lymphoma progression (fPOD24) in follicular lymphoma treated with frontline immunochemotherapy | Matthew Maurer | ![]() |
![]() |
|||
182-P | WhiMSICAL (Waldenstrms Macroglobulinemia Study Involving CArt-wheeL): A Global Patient-derived Data Registry Mapping Treatment and Quality of Life. | Ibrahim Tohidi-Esfahani | ![]() |
![]() |
|||
184-P | Clinico-biological characteristics and treatment outcomes for Agressive Mantle Cell Lymphoma patients included in clinical trials. A LYSA study. | Mathieu Baldacini | ![]() |
![]() |
|||
186-P | Evolution of clonal hematopoiesis in mantle cell lymphoma patients before, during, and after induction chemotherapy and autologous stem cell transplantation | Simon Husby | ![]() |
![]() |
|||
188-P | Early progression of mantle cell lymphoma depicts a high-risk disease with poor response to subsequent therapies and a dismal outcome | Christian Winther Eskelund | ![]() |
![]() |
|||
189-P | The efficacy of ibrutinib in patients with relapsed mantle cell lymphoma after first line intensive chemo-immunotherapy and ASCT a retrospective study from the LWP-EBMT | Claire Burney | ![]() |
![]() |
|||
190-P | IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA | Chiara Rusconi | ![]() |
![]() |
|||
192-P | The Clinical Course of Diffuse Large B-cell Lymphoma (DLBCL) over Time: A Multistate Survival Analysis Using Meta-Data From 13 First-line Randomized Trials | a&287;lar a&287;layan | ![]() |
![]() |
|||
193-P | Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): an individual patient-level analysis across international trial | Norbert Schmitz | ![]() |
![]() |
|||
194-P | The Elderly Project by the Fondazione Italiana Linfomi: a Prospective Comprehensive Geriatric Assessment (CGA) of 1353 Elderly Patients with Diffuse Large B-Cell Lymphoma | Michele Spina | ![]() |
![]() |
|||
196-P | Clinical Characteristics and Outcomes of Stage I Diffuse Large B Cell Lymphoma (DLBCL) in the Rituximab-Era | Sabela Bobillo | ![]() |
![]() |
|||
197-P | Population-based study on different regimens of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma in the Netherlands supports the use of 6 cycles of R-CHOP21 | Djamila Issa | ![]() |
![]() |
|||
198-P | PET-DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL) | Monica Balzarotti | ![]() |
![]() |
|||
199-P | SAFETY ANALYSIS OF AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP NHL29: A PHASE II STUDY OF IBRUTINIB, RITUXIMAB AND MINI-CHOP IN VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED DLBCL | Emma Verner | ![]() |
![]() |
|||
200-P | Prospective multicenter registry for secondary CNS involvement in malignant lymphoma: an update with data from 181 patients | Felicitas Lammer | ![]() |
![]() |
|||
203-P | Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Preliminary results of the R2-GDP-GOTEL Trial | Luis de la Cruz Merino | ![]() |
![]() |
|||
204-P | MSKCC Early Experience Using Radiotherapy as a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma Before CD19 CAR T Therapy | Brandon Imber | ![]() |
![]() |
|||
205-P | Highly Favorable Outcomes with Salvage RT Followed by ASCT in Relapsed & Refractory DLBCL Patients Refractory to Salvage Chemotherapy | Joanna Yang | ![]() |
![]() |
|||
206-P | Post-transplant Lymphoproliferative Disorder in Patients with Lymphoma after Allogeneic Hematopoietic Stem Cell Transplantation | Ayumi Fujimoto | ![]() |
![]() |
|||
207-P | Depth of remission following first line HP-eradication is an independent prognostic factor in gastric MALT lymphoma | Markus Raderer | ![]() |
![]() |
|||
208-P | 90Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma) The Zeno Study | Marangon Miriam | ![]() |
![]() |
|||
209-P | Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including PCR-based clonality analysis | Barbara Kiesewetter | ![]() |
![]() |
|||
210-P | Incidence and Treatment Outcomes of Patients with Transformed Marginal Zone Lymphoma Treated with RCHOP-Like Regimens | Sridevi Rajeeve | ![]() |
![]() |
|||
211-P | Allogeneic hematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: Data from the Japan Society for Hematopoietic Cell Transplantation | Eisei Kondo | ![]() |
![]() |
|||
212-P | PROGNOSTIC FACTORS (PFs) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) TREATED WITH RITUXIMAB-CHOP (RCHOP) RADIOTHERAPY (RT) | Theodoros Vassilakopoulos | ![]() |
![]() |
|||
213-P | Is it radiotherapy necessary for primary mediastinal B-cell lymphoma (PMBL) patients achieving PET negativity after immunochemotherapy? | Marie Trnkova | ![]() |
![]() |
|||
214-P | PD-1 Inhibitor plus Chemotherapy in Relapsed/refractory Primary Mediastinal Large B-cell Lymphoma (PMLBCL) with Aggressive Bulky Disease | Qian Mei | ![]() |
![]() |
|||
215-P | Temozolomide in relapse/refractory primary vitreo-retinal lymphoma (R/R PVRL): a simple, cheap, effective and well tolerated treatment. Result of the largest study on R/R PVRL, from the LOC network | Sylvain Choquet | ![]() |
![]() |
|||
216-P | Clinical features, treatment and outcome of Neurolymphomatosis: Single Institution experienceTitle | Mattia Novo | ![]() |
![]() |
|||
217-P | Bicentric pilot study on age-adapted high-dose chemotherapy and autologous stem cell transplant in newly diagnosed primary CNS lymphoma patients 65 years - MARiTA trial | Elisabeth Schorb | ![]() |
![]() |
|||
219-P | PD-1 blockade in a French series of 13 relapsed / refractory NK/T-cell lymphoma patients | Lucile Couronné | ![]() |
![]() |
|||
220-P | A prospective phase II study of pegaspargase-COEP plus radiotherapy in patients with newly diagnosed extra-nodal NK/T-cell lymphoma | Shaoxuan Hu | ![]() |
![]() |
|||
222-P | CLINICAL OUTCOMES AND DIAGNOSIS-TO-TREATMENT INTERVAL IN PATIENTS WITH NK/T-CELL LYMPHOMA: 7-YEAR FOLLOW-UP OF THE NKEA STUDY | Motoko Yamaguchi | ![]() |
![]() |
|||
223-P | Clinicopathological differences of nodal PTCL with Tfh phenotype from AITL and PTCL, NOS, and detection of prognostic marker of nodal PTCL with Tfh phenotype | Takaharu Suzuki | ![]() |
![]() |
|||
224-P | EVENT FREE SURVIVAL AT 12 MONTHS AND 24 MONTHS AS PREDICTORS FOR OUTCOME OF SYSTEMIC PERIPHERAL T CELL LYMPHOMA: ANALYSIS OF NATIONWIDE THAI LYMPHOMA STUDY GROUP | Kitsada Wudhikarn | ![]() |
![]() |
|||
225-P | Bone Marrow Involvement, but No Blood Involvement, Impairs Survival in Angioimmunoblastic T cell Lymphoma: An Ancillary Study of the REVAIL Trial | Francois Lemonnier | ![]() |
![]() |
|||
227-P | Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results | Matthew Lunning | ![]() |
![]() |
|||
229-P | Anaplastic Large Cell Lymphoma, ALK-Negative: analysis of 235 Cases collected by the T-Cell Project. | monica civallero | ![]() |
![]() |
|||
230-P | Increased Risk of Second Primary Hematologic and Solid Malignancies in Patients with Mycosis Fungoides: Impact on Overall Survival in SEER Registry | Aleksandr Lazaryan | ![]() |
![]() |
|||
233-P | CLINICAL AND BIOLOGICAL PREDICTORS OF OUTCOME IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA: A SINGLE CENTER EXPERIENCE OF 205 PATIENTS. | Gregorio Barilà | ![]() |
![]() |
|||
234-P | Clinical characteristics and outcome of patients with Hodgkins lymphoma older than 60 years treated in Switzerland over the last 17 years | Stefanie Aeppli | ![]() |
![]() |
|||
236-P | DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA (HD): RESULTS OF A PHASE II, PROSPECTIVE STUDY BY FONDAZIONE ITALIANA LINFOMI | Rita Mazza | ![]() |
![]() |
|||
238-P | PET-adapted nivolumab /- ICE as initial salvage therapy in relapsed/refractory Hodgkin lymphoma | Alex Herrera | ![]() |
![]() |
|||
239-P | Transcriptional networks associated with treatment failure in advanced-stage Hodgkin lymphoma: data from the RATHL trial (CRUK/07/033) | Sean Lim | ![]() |
![]() |
|||
241-P | First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of FIL ONLUS | Stefoni Vittorio | ![]() |
![]() |
|||
243-P | CHECKPOINT INHIBITION BEFORE HAPLOIDENTICAL TRANSPLATATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PATIENTS IS ASSOCIATED WITH HIGHER PFS WITHOUT INCREASED TOXICITIES | chiara de philippis | ![]() |
![]() |
|||
244-P | How to donor, stem cell source, and conditioning regimen for haploidentical transplants with post-transplant cyclophosphamide for lymphoma: a report of the EBMT LWP | Ali Bazarbachi | ![]() |
![]() |
|||
246-P | REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE PROGRAM | Catherine Thieblemont | ![]() |
![]() |
|||
247-P | Safety and Preliminary Efficacy in Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in TRANSCEND NHL 001 | Maria Wering | ![]() |
![]() |
|||
249-P | Safety and Efficacy of Axicabtagene Ciloleucel (axi-cel) in Older Patients: Results from The US Lymphoma CAR-T Consortium | Dahlia Sano | ![]() |
![]() |
|||
251-P | Phase 1 Study of AntiCD19 CAR-T Cells with TNFa Transmembrane Domain and 41BB, CD3zeta Costimulatory Domains. Responses in Subjects with Rapidly Progressive Lymphoma | Paolo Caimi | ![]() |
![]() |
|||
252-P | CD19/CD20-redirected bispecific CAR T cell treatment in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma | Yao Wang | ![]() |
![]() |
|||
256-P | Clinical Implications of Cytopenias Beyond Day 30 after Axi-cel Therapy in Patients with Relapsed/Refractory Large B-cell Lymphoma | Paolo Strati | ![]() |
![]() |
|||
257-P | Comprehensive report of anti-CD19 chimeric antigen receptor T-cells (CAR-T) associated Non Relapse Mortality (CART-NRM) from FAERS | Kartik Anand | ![]() |
![]() |
|||
258-P | Safety of Allogeneic Hematopoietic Cell Transplant in Adults after CD19 Targeted Chimeric Antigen Receptor-modified T-cell (CAR-T) Therapy | Mazyar Shadman | ![]() |
![]() |
|||
259-P | Title: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202) | Ahmed Sawas | ![]() |
![]() |
|||
260-P | Ipilimumab plus Lenalidomide for Treatment of Relapsed Disease after Allogeneic Stem Cell Transplantation (AlloSCT) in Patients (pts) with Lymphoid Malignancies | Issa Khouri | ![]() |
![]() |
|||
261-P | Donor lymphocyte infusions induce durable responses in patients with follicular, mantle and T cell lymphomas relapsing after an alloSCT. An EBMT-LWP Study. | Stephen Robinson | ![]() |
![]() |
|||
267-P | Reversal of immune tolerance and increased survival after XPO1 and BTK inhibition in mouse models of primary CNS lymphoma (PCNSL) | Isabel Jiménez | ![]() |
![]() |
|||
269-P | The novel bispecific CD47-CD19 antibody TG-1801 potentiates the activity of ublituximab-umbralisib (U2) drug combination in preclinical models of B-NHL | emmanuel normant | ![]() |
![]() |
|||
271-P | Preliminary results of a Phase 1 dose escalation study of the first-in-class anti-CD74 antibody drug conjugate (ADC), STRO-001, in advanced B-cell malignancies. | Shannon Matheny | ![]() |
![]() |
|||
272-P | Long-term outcome of patients with relapsed/refractory B-cell non- Hodgkin lymphoma treated with bispecific antibody blinatumomab in a phase I trial | Vera Dufner | ![]() |
![]() |
|||
273-P | A first-in-human trial of the novel multi-action therapy tinostamustine (EDO-S101) in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) | Gillian Wain | ![]() |
![]() |
|||
277-P | Safety and efficacy of venetoclax combined with rituximab, ifosfamide, carboplatin and etoposide (VICER) for treatment of relapsed DLBCL: Final results from the Phase 1 Trial | Paolo Caimi | ![]() |
![]() |
|||
278-P | Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Jean-Marie Michot | ![]() |
![]() |
|||
279-P | Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL) and follicular lymphoma (FL) | David Sermer | ![]() |
![]() |
|||
280-P | Safety and efficacy of atezolizumab, obinutuzumab and venetoclax combination for relapsed/refractory non-Hodgkin lymphomas: Results from the safety-run of a LYSA study | Charles Herbaux | ![]() |
![]() |
|||
281-P | Phase 1B Study of ViPOR (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy | Christopher Melani | ![]() |
![]() |
|||
285-P | Title: Improvement of Rituximab administration by premedication with rupatadine, montelukast and their combination | rouslan Kotchetkov | ![]() |
![]() |
June 18-22, 2019 Lugano
![]() |
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|